Xgeva® (denosumab 120mg) – Updated recommendations for calcium monitoring related to the risk of severe symptomatic hypocalcaemia (SSH)

GlaxoSmithKline would like to provide updated recommendations for risk mitigation of severe symptomatic hypocalcaemia (SSH) associated with Xgeva®. Clinical manifestations of SSH associated with XGEVA® have been reported in the post-marketing setting, including QTc interval prolongation, tetany, seizures, coma and altered mental status. Fatal cases of SSH have also been reported. Monitoring of calcium levels is now recommended in all patients at baseline and during treatment, especially in the first weeks of initiating therapy. Please refer to the letter for more information.

Only abstracts of the Dear Healthcare Professional Letters (DHCPL) are provided on this website. Details of these letters can be found in the MOH Alert System, which is accessible via the Health Professionals Portal (HPP), a one-stop portal for all healthcare professionals in Singapore. Dentists, medical doctors and pharmacists may access HPP at https://hpp.moh.gov.sg ↗ (opens in new tab) and follow the procedures below to access the MOH Alert system.

Step 1: Select your profession under ‘For Healthcare Professionals’.

Step 2: Click on ‘Useful links’.

Step 3: Click on ‘MOH Alert’ and log in via Singpass.

Step 4: Click on ‘Drug Alerts’ or ‘Med Device Alerts’ to view the DHCPLs.